Explore /
Poster
/ Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.

Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.

Authors

Makoto Ueno

Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan

Makoto Ueno , Shinichi Ohkawa , Noritoshi Kobayashi , Kazuya Sugimori , Yoshiaki Kawaguchi , Satoshi Kobayashi , Masataka Taguri , Takeharu Yamanaka , Tetsuya Mine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

000007173

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 429)

DOI

10.1200/JCO.2017.35.4_suppl.429

Abstract #

429

Poster Bd #

K13

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

$SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.$